Overview

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Vaccine Against HSV-2 in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent HSV-2 Genital Herpes

Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV) vaccine. The study will be conducted in 2 parts: Part I assessing different formulations of the vaccine candidate in healthy participants aged 18-40 years; Part II assessing the selected formulation of the vaccine candidate in participants aged 18-60 years with recurrent herpes simplex virus type 2 (HSV-2) genital herpes.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GlaxoSmithKline